| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6169084 | CHEPLAPHARM | 2-methyl-thieno-benzodiazepine formulation |
Sep, 2018
(5 years ago) | |
Zyprexa Relprevv is owned by Cheplapharm.
Zyprexa Relprevv contains Olanzapine Pamoate.
Zyprexa Relprevv has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Zyprexa Relprevv are:
- US6169084
Zyprexa Relprevv was authorised for market use on 11 December, 2009.
Zyprexa Relprevv is available in suspension, extended release;intramuscular dosage forms.
Zyprexa Relprevv can be used as a method of treating human suffering from or susceptible to psychosis..
The generics of Zyprexa Relprevv are possible to be released after 30 September, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2012 |
Drugs and Companies using OLANZAPINE PAMOATE ingredient
Market Authorisation Date: 11 December, 2009
Treatment: A method of treating human suffering from or susceptible to psychosis.
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ZYPREXA RELPREVV family patents
